Assessment of factors affecting the mental condition of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

被引:2
|
作者
Gibek, Katarzyna [1 ]
Sacha, Tomasz [2 ]
机构
[1] Jagiellonian Univ Med Coll, Sw Anny St 12,Room 7a, Krakow, Poland
[2] Jagiellonian Univ Med Coll, Chair & Dept Hematol, Krakow, Poland
关键词
cancer; leukemia; psychiatric disorders; QUALITY-OF-LIFE; PSYCHIATRIC MORBIDITY; CANCER; DEPRESSION; ANXIETY; ADJUSTMENT; SYMPTOMS; DISTRESS; PREDICTORS; DISORDERS;
D O I
10.12740/PP/OnlineFirst/130264
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim. The aim of the study was to make a general assessment of mental health, including signs of somatization, depression, anxiety, and functional disorders, in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) and to assess the impact of factors such as the duration of the disease, side effects of therapy, age, and gender on the occurrence of the above-mentioned disorders. Another goal was to identify patients at risk of developing mental disorders. Method. The study involved 91 patients and was conducted at the Hematology Clinic of the University Hospital in Krakow. The following questionnaires were used to assess mental health: survey created by the author, David Goldberg's questionnaire GHQ-28, and the four-dimensional 4DSQ, measuring four dimensions of the mental condition. Results. The average level of the mental condition of the studied group was demonstrated. 29 people with mental disorders were identified. Women and people living alone obtained worse results in almost all dimensions of the questionnaires. The analysis revealed that factors such as age, number of side effects and gender significantly affect mental disorders in the studied group. A significant and positive correlation has been found between the number of side effects and the presence of somatization signs. Mediocre correlations occurred between age and mental disorders and all dimensions of the GHQ-28. Conclusions. The obtained results indicate that attempts should be made to reduce side effects among CML patients. Visiting the psychologist to work on the acceptance of the disease, psychoeducation, behavioral therapy, and contact with a psychiatrist to consider the introduction of pharmacotherapy is recommended. All of these methods may improve a patient's quality of life.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] ASSESSMENT OF PLATELET FUNCTIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
    Sener, Y.
    Akbiyik, F.
    Aydin, S.
    Buyukasik, Y.
    Dikmen, Z. G.
    HAEMATOLOGICA, 2016, 101 : 743 - 743
  • [2] Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
    Pagnano, Katia B. B.
    Assuncao, Paola Morelato
    Zullli, Roberto
    Delamain, Marcia T.
    Duarte, Gislaine Oliveira
    Lorand-Metze, Irene
    De Souza, Carmino A., Sr.
    BLOOD, 2015, 126 (23)
  • [3] Vascular complications in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    Cho, Hee Jeong
    Sohn, Sang-Kyun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (04): : 224 - 233
  • [4] Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
    Sawyers, CL
    SEMINARS IN HEMATOLOGY, 2001, 38 (03) : 15 - 21
  • [5] Adherence assessment in Chronic Myeloid Leukaemia patients treated by tyrosine kinase inhibitors
    Daouphars, M.
    Ouvry, M.
    Lenain, P.
    Rouvet, J.
    Varin, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 414 - 415
  • [6] Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
    Engelbrecht, Fernanda F.
    Miranda, Eliana C.
    Delamain, Marcia Torresan
    Duarte, Gislaine Borba
    Souza, Carmino Antonio
    De Paula, Erich V.
    Pagnano, Katia B.
    BLOOD, 2019, 134
  • [7] STUDY OF THE MECHANISMS OF THROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
    Agula, S.
    Cuenca-Zamora, E.
    Lis, M. J.
    Noya-Pereira, M. S.
    Gutierrez-Garcia, V
    Garcia-Hernandez, M. C.
    Perez-Lopez, R.
    Fernandez, M. J.
    Palomera, L. R.
    Orti, G.
    Rosell, A.
    Vallansot, R.
    Angona-Figueras, A.
    Xicoy, B.
    Conesa, V
    Puerta, J. M.
    Perez-Encinas, M.
    Cortes, M.
    Hernandez-Boluda, J. C.
    Carreno, G.
    Mora, E.
    Giraldo, P.
    Vicente, V.
    Steegman, J. L.
    Ferrer-Marin, F.
    HAEMATOLOGICA, 2021, 106 (10) : 3 - 3
  • [8] Tyrosine kinase inhibitors in chronic myeloid leukemia
    Sawyers, CL
    Druker, B
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
  • [9] Assessment of molecular response to tyrosine kinase inhibitors in Tunisian Patients with Chronic Myeloid Leukemia
    Frikha, Rim
    Kassar, Olfa
    Elloumi, Moez
    Kamoun, Hassen
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1826 - 1831
  • [10] ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA
    Yadrikhinskaya, V. N.
    Mulina, I. I.
    Sannikova, A. N.
    Palshina, A. M.
    Sleptsova, S. S.
    Aleksandrova, T. N.
    YAKUT MEDICAL JOURNAL, 2016, (04): : 30 - 33